Drugs / Angiotensin Therapeutic Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00702221 | Jun 2008 → Jun 2009 | hypertensive disorder | BTG International Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Angiotensin Therapeutic Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00702221 ↗ |
| Known as | ATV | “Angiotensin Therapeutic Vaccine (ATV), which contains the novel adjuvant, CoVaccine HT™ , is being developed for the treatment of high blood pressure (hypertension)” NCT00702221 ↗ |
| Action | Inhibit | “bind to angiotensin, so suppressing its actions” NCT00702221 ↗ |
| Modality | Vaccine | “Angiotensin Therapeutic Vaccine” NCT00702221 ↗ |
| Route | Intramuscular | “given as 3 separate intramuscular injections into the arm” NCT00702221 ↗ |